Dr TIM CARD tim.card@nottingham.ac.uk
Clinical Associate Professor
Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
Card, Timothy; Ungaro, Ryan; Bhayat, Fatima; Blake, Aimee; Hantsbarger, Gary; Travis, Simon
Authors
Ryan Ungaro
Fatima Bhayat
Aimee Blake
Gary Hantsbarger
Simon Travis
Abstract
© 2019 John Wiley & Sons Ltd Background: Vedolizumab is a gut-selective antibody to α4β7integrin approved to treat moderate-to-severe Crohn's disease and ulcerative colitis in adults. Inflammatory bowel disease (IBD) and immunosuppressant use are associated with increased risk of malignancy. Aim: To analyse the incidence of malignancy with vedolizumab treatment in the GEMINI long-term safety (LTS) study and post-marketing (PM) setting. Methods: Malignancy data from the LTS study (May 2009 to May 2018), and data from the vedolizumab Global Safety Database (20 May 2014 to 19 May 2018), were identified using Medical Dictionary for Regulatory Activities coding. The number of patients experiencing malignancies in the LTS study (excluding malignancies within 1year following vedolizumab initiation) was indirectly standardised against the number expected, using age- and sex-specific rates in patients with IBD from Optum's Clinformatics™ Data Mart (CDM) database. Results: Among 1785 patients with ≥1year of follow-up post-vedolizumab initiation in the LTS study (total 5670 patient-years), observed numbers of malignancies were similar to those expected compared with CDM data (31 vs 29; ratio of observedto expected events=1.08; P=0.71; 95% confidence intervals [CI] 0.73, 1.53). The most common malignancies were renal and bladder (6). PM, 293 patients reported 299 malignancies (including malignancies within 1year following vedolizumab initiation), in approximately 208050 patient-years of vedolizumab exposure. Lower gastrointestinal malignancies were most common (59). Conclusions: The number of malignancies in the LTS study was similar to that expected from an IBD population with no statistically significant differences, although few confounders could be corrected for. Limitations of PM safety reporting require consideration; however, the number of malignancies with vedolizumab appeared low.
Citation
Card, T., Ungaro, R., Bhayat, F., Blake, A., Hantsbarger, G., & Travis, S. (2020). Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data. Alimentary Pharmacology and Therapeutics, 51(1), 149-157. https://doi.org/10.1111/apt.15538
Journal Article Type | Article |
---|---|
Acceptance Date | Sep 23, 2019 |
Online Publication Date | Nov 20, 2019 |
Publication Date | 2020-01 |
Deposit Date | Sep 27, 2019 |
Publicly Available Date | Nov 21, 2020 |
Journal | Alimentary Pharmacology and Therapeutics |
Print ISSN | 0269-2813 |
Electronic ISSN | 1365-2036 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 51 |
Issue | 1 |
Pages | 149-157 |
DOI | https://doi.org/10.1111/apt.15538 |
Public URL | https://nottingham-repository.worktribe.com/output/2664462 |
Publisher URL | https://onlinelibrary.wiley.com/doi/full/10.1111/apt.15538 |
Files
Card Et Al PV Malignancy Manuscript For Resubmission R1 17-Sept-19
(525 Kb)
PDF
Card Et Al. PV Malignacy Manuscript Figure 1 For Resubmission 17-Sept-19
(309 Kb)
PDF
Card Et Al. PV Malignancy Manuscript Appendices For Resubmission 17-Sept-19
(128 Kb)
PDF
You might also like
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: digital-library-support@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search